Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology
NCT03244020Phase 4Enrolling by invitation
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2018
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin and aspirin in venous thromboembolism (VTE) (6 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Venous thromboembolism at 6 months. Started Feb 2018; status: enrolling by invitation.
02
Drugs
enoxaparinaspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03244020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244020.